ProCE Banner Activity

Expert Insight on Key Updates and New Clinical Trial Data From the ESGO 2023 Congress Informing Treatment for Cervical, Ovarian, and Endometrial Cancers

Conference Coverage
Podcast Episodes

In this podcast episode, listen to Alexandra Leary, MD, PhD, and Domenica Lorusso, MD, PhD, discuss key updates and new clinical trial data for gynecologic cancers presented at the ESGO 2023 Congress.

Released: October 13, 2023



Alexandra Leary

Alexandra Leary, MD, PhD

Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab, ISERM U981
Institut Gustave Roussy
Past-President, GINEGEPS, GINECO Group on Early Phase Trials
Villejuif, France

Domenica Lorusso

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Provided by

Provided by Clinical Care Options (CCO)

ProCE Banner


Supported by educational grants from AstraZeneca, Genmab, GlaxoSmithKline, Merck Sharp & Dohme Corp., Novocure Inc., and Seagen Inc.




Merck Sharp & Dohme Corp.



Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply new data in cervical, endometrial, and ovarian cancers to clinical practice to expand treatment options and improve outcomes for patients with gynecologic malignancies

  • Assess predictive biomarkers in gynecologic cancers to guide treatment selection and clinical trial eligibility

  • Plan individualized treatment strategies, incorporating novel therapies and combination strategies as appropriate, for patients with cervical, endometrial, and ovarian cancers

  • Provide education and support throughout all stages of diagnosis and treatment to populations of patients with gynecologic cancers who are at increased risk for poor prognosis